



- (51) International Patent Classification:
A61K 9/16 (2006.01) A61K 31/4178 (2006.01)
- (21) International Application Number:
PCT/IB2015/000997
- (22) International Filing Date:
11 March 2015 (11.03.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/951,074 11 March 2014 (11.03.2014) US
61/951,092 11 March 2014 (11.03.2014) US
61/951,112 11 March 2014 (11.03.2014) US
62/040,136 21 August 2014 (21.08.2014) US
- (71) Applicant: REDHILL BIOPHARMA LTD. [IL/IL]; 21 Ha'arba'a Street, Tel-aviv (IL).
- (72) Inventors: FATHI, Reza; 260 Forest Avenue, Oradell, NJ 079649 (US). RADAY, Gilead; 4025 Middlefield Road, Palo Alto, CA 94303 (US). GOLDBERG, Guy; Dizengof 6, Apartment 2, Tel-aviv (IL).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

- AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- Published:
— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

- (54) Title: ONDANSETRON EXTENDED RELEASE SOLID DOSAGE FORMS FOR TREATING EITHER NAUSEA, VOMIT-ING OR DIARRHEA SYMPTOMS
- (57) Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.

